Unity, on the rebound after catastrophe, shows promising results in early eye disease trial

Unity Biotechnology CEO Anirvan Ghosh, Ph.D. (Unity)
Nearly a year after dropping its lead program and sinking its stock, Unity Biotechnology appears to be coming back on track with positive data in its phase 1 study in patients with advanced vascular eye disease. 
The anti-aging biotech said Tuesday its small-molecule inhibitor of Bcl-xL, a senolytic therapeutic, was well tolerated in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD).
Unity shares were up about 9% in early trading Tuesday morning.
The study of UBX1325 was conducted in patients for whom anti–vascular endothelial growth factor (anti-VEGF) therapy was not considered to be beneficial anymore. Anti-VEGF treatments include Roche's Lucentis, Regeneron's Eylea, Novartis' Beovu and Roche's Avastin.

Related Keywords

Boston ,Massachusetts ,United States ,Roche Lucentis ,Roche Avastin ,Anirvan Ghosh ,Novarti Beovu ,Jeffrey Heier ,Regeneron Eylea ,Retina Research At Ophthalmic Consultants Of Boston ,Vitreoretinal Service ,Unity Biotechnology ,Retina Research ,Ophthalmic Consultants ,போஸ்டன் ,மாசசூசெட்ஸ் ,ஒன்றுபட்டது மாநிலங்களில் ,ஜெஃப்ரி ஹேஎர் ,விழித்திரை ஆராய்ச்சி இல் கண் ஆலோசகர்கள் ஆஃப் போஸ்டன் ,விதிறெோரேதினாள் சேவை ,ஒற்றுமை உயிரி தொழில்நுட்பவியல் ,விழித்திரை ஆராய்ச்சி ,கண் ஆலோசகர்கள் ,